GlobeNewswire·Mar 25, 2026, 4:01 PM ET

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

NKX019 dose escalation advanced to 4 billion cells per dose on days 0, 3 & 7 for a total of 12 billion cells per cycle.
Initial clinical data from Ntrust-1 & Ntrust-2 trials are targeted for presentation at a medical conference in 2026.
Cash balance of $295.1 million as of December 31, 2025 is expected to fund operations into 2029.
Enrollment continues in Ntrust-1 & Ntrust-2 trials for autoimmune diseases including generalized myasthenia gravis & systemic lupus erythematosus.
Full year 2025 research & development expenses were $90.4 million while general & administrative expenses were $31.6 million.
Net loss for the full year 2025 was $104.1 million ($1.41 per share) with a fourth quarter net loss of $27.4 million ($0.37 per share).
Ntrust-1 & Ntrust-2 are multi-center open-label dose-escalation trials assessing NKX019 safety & potential for durable remission via B-cell depletion.
Patients in the trials receive a three-dose cycle of NKX019 following lymphodepletion without supplemental cytokines or antibody-based therapeutics.
NKX019 is an allogeneic CD19-targeted CAR-NK cell therapy engineered with a membrane-bound form of interleukin-15.
Nkarta's cash, cash equivalents, restricted cash & investments totaled $295.1 million as of December 31, 2025.